• Bindon, C.I., Hale, G., Brüggemann, M. & Waldmann, H. (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. Journal of Experimental Medicine, 168, 127142.
  • Boross, P. & Leusen, J.H. (2012) Boosting antibody therapy with complement. Blood, 119, 59455947.
  • Brekke, O.H., Michaelsen, T.E. & Sandlie, I. (1995) The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunology Today, 16, 8590.
  • Dechant, M., Vidarsson, G., Stockmeyer, B., Repp, R., Glennie, M.J., Gramatzki, M., van De Winkel, J.G. & Valerius, T. (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood, 100, 45744580.
  • Glennie, M.J., French, R.R., Cragg, M.S. & Taylor, R.P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 44, 38233837.
  • Grillo-Lopez, A.J., White, C.A., Varns, C., Shen, D., Wei, A., McClure, A. & Dallaire, B.K. (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Seminars in Oncology, 26, 6673.
  • van Meerten, T., van Rijn, R.S., Hol, S., Hagenbeek, A. & Ebeling, S.B. (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research, 12, 40274035.
  • Michaelsen, T.E., Garred, P. & Aase, A. (1991) Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. European Journal of Immunology, 21, 1116.
  • Stapleton, N.M., Andersen, J.T., Stemerding, A.M., Bjarnarson, S.P., Verheul, R.C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., Jonsdottir, I., van der Schoot, C.E. & Vidarsson, G. (2011) Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Communications, 2, 599.
  • Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G.J. & Glennie, M.J. (2004) Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against Non-Hodgkin's lymphoma. Blood, 104, 17931800.